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Since the operationalization of the clinical criteria indicating an ultra-high risk for psychotic disorder over 
two decades ago, a number of interventions have been trialled, with the aim of preventing onset of 
psychotic disorder and improving outcomes. Among the most promising has been dietary supplementation 
with long-chain omega-3 polyunsaturated acids (PUFA), which in a single-centre study involving 81 
participants, was shown to significantly reduce the risk of transition to psychosis over a 12-month period, 
as well as improving symptomatic and functional outcomes, an effect that persisted long-term (median 6.7 
years). The current trial aimed to replicate these findings in a large-scale multi-centre study. 
Objective 
To determine whether treatment with PUFA, in combination with a high-quality psychosocial intervention, 
cognitive behavioural case management (CBCM), is more effective than placebo plus CBCM in preventing 
transition to psychosis and improving outcomes in young people at ultra-high risk for psychosis. 
Design, setting and participants 
A randomized, double-blind, placebo-controlled trial was conducted in 10 specialized early psychosis 
treatment services in Australia, Asia, and Europe, involving a total cohort of 304 participants. 
Interventions 
The intervention consisted of a daily dose of 1.4 g omega-3 PUFA or placebo (paraffin oil), plus up to 20 
sessions of CBCM over the 6-month study period. 
Main outcomes and measures 
The primary outcome was transition to psychosis status at 6 months, as defined by the CAARMS. The 
secondary outcomes were general levels of psychopathology and functioning, as assessed by the BPRS, 
SANS, MADRS, YMRS, SOFAS and the Global Functioning: Social and Role scales. 
Conclusions and relevance 
This trial failed to replicate the findings of the original single-centre trial, principally due to the lower than 
expected transition rate and a substantial improvement in outcome in both groups. No difference was 
observed between the transition rates of both groups, which is consistent with omega-3 PUFAs lacking any 
efficacy. However, the low transition rate clearly inhibited our ability to test the main hypothesis that 
omega-3 PUFAs are effective in reducing the risk of first episode psychosis. The low transition rate could be 
because the sample was insufficiently enriched, or more likely, that the other treatments received 
produced a ceiling effect, beyond which omega-3 PUFAs did not confer additional benefits. Further analysis 
and additional research is necessary to enable definitive conclusions to be drawn. 
Trial Registration 
Australian New Zealand Clinical Trials Registry ACTRN 12608000475347 
 
Word count (main text): 3,589 
  
Psychotic illnesses, and especially schizophrenia, typically emerge from initially subtle and relatively non-
specific symptoms, building through a prodromal period of sub-threshold positive symptoms to cross a 
somewhat arbitrary threshold that enables a first episode of psychosis to be diagnosed.1 The operational 
definition of the “at-risk” or “ultra-high risk” (UHR) mental state, 2, 3 which prospectively identifies people at 
incipient risk of progression to full-threshold psychosis, has catalyzed an intense research effort as well 
significant reforms to clinical care. These patients are typically distressed, functionally impaired and 
manifest a need for clinical care on the basis of their current symptoms, in addition to the potential benefit 
of reducing the risk for progression to psychosis.4, 5 A series of research studies has now validated the UHR 
criteria and enabled the study of a range of treatment strategies to relieve distress, improve functioning 
and reduce the risk for progression to a psychotic illness.2, 3, 6-14 
To date, 11 trials assessing psychosocial or pharmacological interventions, alone or in combination, have 
been carried out in UHR cohorts. A recent meta-analysis of these trials has shown that these interventions 
are effective, with an overall risk reduction of 54% at 12 months, with a NNT of 8 (4–13).15 All treatments in 
these studies appeared to reduce the risk of progression to psychosis, at least during the first 6–12 months. 
In line with the clinical staging model of illness,16-20 during the earliest stage of illness, safer interventions, 
such as long-chain omega-3 polyunsaturated fatty acids (PUFA) and cognitive behavioural therapy (CBT), 
should be regarded as the preferred option for first-line treatment. CBT, a well-established and safe 
psychosocial intervention, adapted for this stage of illness, has been found to be effective in many, though 
not all, of the published trials.21-26 However, the most striking result from the trials to date was the finding 
that omega-3 PUFA were greatly superior to placebo in reducing the risk for transition to psychosis, and 
psychiatric morbidity in general, not only during the period of treatment, but for a prolonged period 
(median 6.7 years) subsequently.27, 28 Omega-3 PUFA are safe, beneficial to health in many ways, and 
represent a simple and relatively inexpensive potential treatment strategy. The initial omega-3 study was 
therefore clearly worthy of attempted replication.  
Methods 
Study design and setting 
This was a randomized, double-blind, placebo-controlled 6-month treatment trial of omega-3 PUFA, 
followed by an additional 6-month follow-up period, in 304 participants who received either omega-3 PUFA 
together with cognitive behavioural case management (CBCM), or placebo with CBCM. The total study 
period was 12 months. Assessments were made at baseline, 6 and 12 months after trial entry. In addition, 
assessments of psychopathology were conducted monthly during the first 6 months and also at Month 9. 
The 6 and 12-month results are presented here. The study was performed in accordance with the 
Declaration of Helsinki and is consistent with ICH Good Clinical Practice.29 The National Health and Medical 
Research Council of Australia National Statement on Human Research was also adhered to, and appropriate 
ethical approval was obtained by each site, and any local regulatory requirements met before the trial 
commenced. For complete details of the study methodology, see Markulev et al.30 
Help-seeking individuals attending the trial centres were eligible to participate if they were aged 13–40 
years and met criteria for one or more of the UHR groups: attenuated psychotic symptoms, transient 
psychosis, or genetic risk. In a variation to our previous UHR intervention studies, all participants either had 
a low level of functioning (SOFAS < 50) sustained for at least a year or had experienced a significant 
decrease in their functioning (a 30% or greater reduction in their SOFAS score) over the past year.31 
Participants were required to be able to give informed consent. Exclusion criteria included a previous 
psychotic episode of 7 days or longer, current symptoms due to acute intoxication, organic brain disease, 
serious developmental disorder, abnormal coagulation profile or thyroid function, physical illness with a 
psychotropic effect, current treatment with mood stabilizers, past neuroleptic exposure to a total lifetime 
haloperidol equivalents dose of >50 mg, IQ of <70, dangerous behaviour, aggression or suicidality, 
pregnancy, or current supplementation with omega-3 PUFA.30 
Randomization 
Participants were randomized at study entry to either the omega-3 PUFA plus CBCM group, or the placebo 
plus CBCM group via an online electronic data management system. Randomization was stratified by site 
and total score on the Montgomery-Asberg Depression Rating Scale (MADRS),32 as both depression and 
antidepressants may impact on UHR symptoms and illness progression.33-36 All participants, those involved 
in delivering interventions, assessing outcomes and data entry were blind to group assignment. The trial 
statistician (HPY) was unblinded at the analysis stage. 
Study interventions 
Participants received either omega-3 PUFAs or placebo together with clinical care with CBCM for the 6-
month intervention phase, after which both the omega-3 PUFAs and placebo were ceased, although 
patients could continue to access CBCM on the basis of need throughout this 6-month follow-up.30 A total 
of 125 participants continued to receive CBCM after the 6-month follow-up visit, with a mean of 4.1±3.71 
(range 1–16) sessions attended. 
For the first 12 months of the study, antidepressants (SSRIs only) were permitted for moderate–severe 
major depression (MADRS score ≥21 for at least two consecutive weeks), and benzodiazepines were 
permitted for anxiety. The use of antipsychotics or mood stabilizers was not permitted at any time during 
the trial unless a participant was withdrawn from the study prior to 12 months and these treatments were 
deemed necessary according to clinical guidelines. 
The study medication comprised a daily dose of four gelatine capsules throughout the 6-month treatment 
period. Participants were dispensed bottles of capsules, with each capsule containing either: (i) 0.650–
0.750 g concentrated marine fish oil (active intervention; containing 840 mg EPA and 560 mg DHA or 
approximately 1.4 g omega-3 PUFAs/day); or (ii) 0.650–0.750 g of paraffin oil (placebo intervention). This 
dose was similar to that in our previous study.27 
Outcome measures 
The primary outcome was transition to psychosis status at 6 months, with transition defined on the basis of 
operationalized criteria and assessed with the Comprehensive Assessment of the At-Risk Mental State 
(CAARMS).31 Diagnoses (both psychotic and non-psychotic) were determined with the Structured Clinical 
Interview for DSM-IV-TR Axis I Disorders, and the secondary measures included the BPRS,37 SANS,38 
MADRS,32 YMRS,39 SOFAS40 and the Global Functioning: Social and Role scales.41 
Adherence to the study medication was assessed monthly for each participant based on capsule count. The 
average adherence rating over the 6-month intervention period was then computed and categorized as 
either adherent, with ≤25% of capsules returned, or non-adherent, with >25% of capsules returned. 
Adverse events and serious adverse events were monitored throughout the study, and were assessed at 
each visit during the intervention phase and classified into categories for further analysis. 
Statistical analysis 
The study was powered to detect a 13% difference in the transition rates between the two treatment 
groups, with the 6-month transition rate in the placebo group assumed to be 15%.30 The primary analysis 
used the intention-to-treat (ITT) approach and compared the difference in transition rates between the 
treatment groups using survival analysis with the stratified log-rank test and Cox regression with 
recruitment site and baseline MADRS score (<21 and ≥21) used as stratifying factors. General linear 
modelling and linear mixed effects model analysis were used to compare the secondary outcomes 
(symptomatology and functioning) for the two groups. Further analysis to compare the treatments was 
conducted by taking adherence into account for both the primary and the secondary outcomes. 
Risk class analysis was also undertaken using demographic characteristics (age, gender, race, years of 
education, duration of untreated symptoms) and symptom and functioning measures (BPRS, SANS, MADRS, 
YMRS, SOFAS, global functioning) as potential risk factors, to identify a subgroup of patients who might be 
at a relatively higher risk of transition. The two treatments were then compared within this subgroup in 




The study cohort consisted of 304, with 153 randomly assigned to omega-3 PUFA treatment and 151 to 
placebo. The baseline characteristics of both groups were similar (Supplementary Tables 1 and 2). Fourteen 
of the 153 (9.1%) particpiants from the omega-3 group, and 18/151 (11.9%) from the placebo group 
discontinued the intervention prematurely (i.e., prior to 6 months). Twenty-four (15.7%) participants from 
the omega-3 group were unable to be contacted and one became pregnant, while 22 (14.6%) participants 
were unable to be contacted from the placebo group, meaning that in total 79 (26%) participants were lost 
to follow-up (Figure 1). The mean duration of untreated illness was 891.1 days (median 467, SD 969.1 days) 
in the omega-3 group and 897.6 days (median 431.5, SD 115.6 days) in the placebo group. 
Efficacy 
Primary outcome measure 
The stratified log-rank test indicated no significant difference between the two treatments in terms of 
transition rate (p=0.76). The Kaplan-Meier estimated 6-month transition rates were 5.1% (95%CI 1.3–8.7) in 
the control group, and 6.7% (95%CI 2.3–10.8) in the omega-3 group. At 12 months, the transition rates 
were 11.2% (95% CI 5.5–16.7) in the control group and 11.5% (95% CI 5.8–16.9) in the omega-3 group 
(Figure 2). Cox regression, again stratified for recruitment site and baseline MADRS score, also showed no 
significant difference between the two groups (hazard ratio 1.1; 95% CI 0.55–2.23; p=0.76). 
Secondary outcome measures 
General linear model analysis, with an a priori significance threshold of p<0.05 and no adjustment for 
multiple testing, was used to compare the treatments in terms of changes in the symptom and functioning 
measures between baseline and the 6- and 12-month follow-up visits. Two of these measures showed a 
trend towards improvement at Month 6: the MADRS (p=0.093) and the SOFAS (p=0.066), while a 
statistically significant improvement was seen on the global functioning role scale (p=0.017). However, the 
direction of these changes was in favour of the placebo group. We suggest these are either chance findings, 
or that for reasons which are not clear, the placebo group may have benefited more from the psychosocial 
and other treatment interventions. No statistically significant difference was seen between the groups in 
any of the measures at Month 12 (Table 1). Linear mixed effects modelling was used to compare the two 
treatments in terms of the rate of improvement over time for each of the symptom and functioning 
measures. Although there was a significant improvement over time for each measure, the rate of 
improvement did not significantly differ between the two treatments on any of the measures (Table 1). 
  
Adverse events 
Adverse events were assessed at baseline and monthly during the intervention phase, and then at the 6- 
and 12-month follow-up visits. No statistically significant group differences were observed between the 
treatment and placebo groups (Supplementary Table 3). 
Adherence and concomitant medication 
The proportion of adherent participants was 43.1% for the omega-3 group and 41.1% for the placebo 
group. However, a total of 83 subjects had missing data for the capsule counts (35 from the omega-3 PUFA 
group, 48 from the placebo group), 9 of whom transitioned to psychosis. In order not to lose subjects from 
the analysis, these 83 subjects were assumed to be non-adherent. Figure 3 shows the survival curves 
comparing the two groups for the adherent and non-adherent participants, respectively. As expected, the 
transition rate was lower in the adherent participants; however, stratified log-rank tests comparing the two 
treatment groups showed that there was no significant difference between them regardless of adherence 
status (adherent subjects, p=0.38, non-adherent subjects, p=0.95; Figure 3). 
The symptom and functioning measures were further analyzed by taking adherence into account, again 
using general linear modelling and a linear mixed effects model. Again, no significant difference between 
the two treatment groups was found (p>0.14 for all measures), irrespective of adherence status. 
The mean number of CBCM sessions attended was 11.2 (SD 6.4) for the omega-3 group and 10.3 (6.0) for 
the placebo group. The overall median number of CBCM sessions attended was 8. Again, stratified log-rank 
tests showed that there was no significant difference between the treatment groups in terms of transition 
rate for those with a number of CBCM sessions equal to or below the median (p=0.31), as well as for those 
above the median (p=0.50). 
Concomitant medication use after randomization included antidepressants in 98 (64.1%) of those in the 
omega-3 group and 91 (60.3%) of those in the placebo group (p=0.57) and anxiolytics in 32 (20.9%) of the 
participants in the omega-3 group and 44 (29.1%) of those in the placebo group (p=0.13). 
Risk class analysis 
Risk class analysis was undertaken in an effort to identify participants at highest risk of transition, in order 
to assess the effectiveness of omega-3 PUFA in this subgroup. Demographic characteristics and symptom 
and functioning measures were used as potential risk factors and their significance on transition rate was 
determined using Cox regression analysis in the placebo group to remove any potential intervention effect. 
The only measures found to be significant were the BPRS total score (p=0.025) and the MADRS total score 
(0.009). Because these two measures were highly correlated (Pearson correlation 0.67), the MADRS score 
was chosen as the stratifying factor for this analysis as it had a lower p-value, no missing values, and was 
one of the stratifying variables for the randomization. A cut-off score of 14 for MADRS score was found to 
correspond to the most significant p-value (p=0.001). This score was considered valid as the placebo 
subjects who had a MADRS total score <14 had an estimated 1-year transition rate of 0%, whereas those 
with a score ≥14 had an estimated 1-year transition rate of 16.5%. However, when the transition rates of 
the two treatment groups were compared within the “high-risk” (i.e., those with a MADRS score ≥14) 
subjects, no significant difference was found (p=0.36) (Figure 4). 
Discussion 
To our knowledge, this is the first randomized, placebo-controlled multi-centre trial to test the efficacy of 
long-chain omega-3 PUFAs in preventing transition to psychosis in ultra-high risk young people. Although 
omega-3 PUFAs were well tolerated, they did not demonstrate an advantage over placebo in the 
prevention of psychosis at 6- or 12-month follow-up. The two treatment groups also did not differ 
significantly on secondary outcome measures of psychiatric symptoms and functioning. These findings 
represent a clear failure to replicate our earlier single-centre trial in 81 participants, in which omega-3 
PUFA supplementation showed highly significant and clinically important results, reducing both the risk for 
progressing to a first episode of psychosis and leading to significant symptomatic and functional 
improvements,27 which have now been sustained for a median of 6.7 years.28 
While one obvious possible explanation for this non-replication is that omega-3 PUFA supplementation is 
not effective for preventing the onset of psychosis, other explanations may have been responsible. The 12-
month transition rate was lower than expected in this trial, and well below that in our previous trial, with 
an overall proportion of 10.5% (32 of 304 participants). In our previous study, the transition rates were 
16.1% at 12 months and 24.7% at 7 years (median) after baseline, respectively. There are two possible 
explanations for this lower transition rate. Firstly, the manualized CBCM intervention and the high level of 
antidepressant treatment received by both treatment groups in the current study may have been 
sufficiently effective to have produced a ceiling effect, beyond which there was no scope for omega-3 PUFA 
to confer additional benefit. In support of this possibility is the fact that the placebo group in the original 
trial failed to show the level of symptomatic and functional improvement seen in the current study.42 
Secondly, the sample may have been insufficiently enriched for risk of transition. At first glance the low 
transition rate might be regarded as having reduced the power of the study to detect an effect; however, 
there was no trend for efficacy of the omega-3 PUFAs, so more power through a larger sample size would 
not be likely to address this issue. Rather, the better outcomes, if produced by better treatment or lower 
risk in the sample, are more appropriately seen as having prevented the main hypothesis from being tested 
through a ceiling effect. Hence the study is best described as a “failure to replicate” the original findings. It 
remains possible that omega-3 PUFAs may be beneficial in the absence of other treatments, or possibly in a 
subsample of cases. Longer term follow up, subgroup analysis and additional studies may clarify these 
issues. 
In relation to these possible interpretations, lower transition rates have been observed over the last 
decade,43, 44 and it has been suggested that the increasing awareness of UHR symptoms may have led to a 
more rapid referral of young people, resulting in a reduced duration of untreated symptoms.45, 46 However, 
this does not seem to have been the case in the current study, and furthermore the level of baseline 
symptoms and functioning is similar to those in earlier studies, including the original omega-3 trial. The 
decline in transition rates could also indicate that psychosocial treatment is more effective in these earlier 
stages of illness, an important point for the design of future studies. Many trials have shown that CBT is 
effective in delaying and reducing transition, 15 and in contrast to our original study, all patients in the 
present study received substantial levels of a high-quality CBT-based intervention. In addition, the high 
proportion of participants who received antidepressant medication (62% compared to 10% in the original 
study) may also have contributed to the low overall transition rate. Previous studies have suggested, but 
not demonstrated, an effect of antidepressant medication in decreasing transition rate in UHR samples.33-36 
In this study, antidepressant medication was prescribed to those participants who were more symptomatic 
and depressed, and who therefore were at higher risk of transition to psychosis, thus potentially having a 
selectively greater effect on reducing the overall transition rate. Given the still low, but rising, 12-month 
transition rate observed in the present study, a longer-term follow-up in this cohort is warranted, and a 24-
month follow-up is currently being completed. It is possible, based on the long-term efficacy of omega-3 in 
the original sample that a differential trajectory could appear later in the omega-3 group; however, in the 
earlier trial there was an early, as well as a sustained, effect. It is possible that in the current study the early 
effect was masked by the potency of the other treatments. 
Adherence was modest in this study: 41.1% in the placebo group and 43.1% in the fish oil group. In 
comparison, the mean rate of adherence to study medication in the Vienna omega-3 study was 81.4% in 
the omega-3 group and 75.4% in the placebo group.27 This comparatively lower adherence may have made 
it even more difficult to detect statistically significant differences in the secondary outcome measures. 
Strengths of the study include the randomized, placebo-controlled design, the use of standardized inclusion 
and exit criteria, inter-rater reliability testing, the monitoring of treatment adherence, and the confirmation 
at 12-month follow-up by means of SCID and case review that all people who met the exit criteria had 
made transitions to genuine psychotic disorders. 
A limitation of this study is that the use of non-study omega-3 PUFA supplements cannot be excluded. In 
pharmaceutical trials, the control group is not exposed to the study drug. In contrast, in omega-3 PUFA 
trials, the test agent may be present in both the experimental and control groups,47 because the non-study 
intake of omega-3 PUFAs cannot be prevented. It is thus possible that non-study omega-3 intake may have 
decreased the difference in omega-3 status between the treatment groups. As demonstrated by cell 
membrane fatty acid data, there was no substantive non-study fish oil supplement intake in our earlier 
trial. However, it is possible that non-study fish oil supplementation or increased fish intake may have 
occurred in the present trial, as both the awareness of the potential health benefits of omega-3 PUFAs and 
the availability of fish oil supplements has sharply increased over the last decade. 
It is also possible that omega-3 PUFAs may have stronger effects in subgroups characterized by certain 
biological or phenotypic factors (i.e., fatty acid profiles, inflammatory markers, oxidative stress markers 
and/or higher levels of negative symptoms28), and thus can be considered as moderators of the clinical 
response in these individuals 48. In this regard, it has recently been shown that omega-3 PUFAs are 
specifically effective in people with high levels of inflammation.49 In a next step, subgroup analyses using 
information on baseline membrane fatty acid levels and inflammatory markers will be carried out to 
address this question. We are also investigating whether biological measures of omega-3 PUFA intake that 
accurately define adherence to study medication as well as non-study intake (i.e., independent of group 
allocation), such as changes in erythrocyte membrane fatty acid levels, will provide a clearer view of 
whether omega-3 PUFAs were beneficial in subgroups of this cohort. However, irrespective of the 
outcomes of these analyses, it is already clear that when used in addition to high quality biopsychosocial 
treatment, the benefits of omega-3 PUFAs appear to be more modest than originally thought. 
In summary, this trial has failed to replicate the findings of our previous study.27 No other multi-centre 
clinical trials have so far been completed that have examined the effect of omega-3 PUFAs in the 
prevention of psychosis, although some are currently underway. These, ongoing analysis of the data from 
the current study, and future research, will help to ultimately determine whether omega-3 PUFAs have a 
role in the reduction of risk and early treatment of psychotic disorder. 
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Figure 1: CONSORT diagram of participant distribution. 
Figure 2: Survival curves of the rate of transition to psychosis in the omega-3 and placebo groups. 
Figure 3: Survival curves for the rate of transition in the two groups, based on adherence status. 
Figure 4: Survival curves for the rate of transition in high-risk subjects (those with a baseline MADRS score ≥ 
14). 
Table 1: General linear model analysis comparing the placebo and omega-3 groups in terms of change between baseline and follow-up (Months 6 and 12), and 
linear mixed model analysis comparing the two treatments in terms of rate of change over time. 
General linear model analysis Linear mixed effects model analysis 
 








Mean SD p-value1 Mean SD p-value1 
BPRS total 
Placebo -7.4 8.5 0.364 -7.8 8.4 0.999 
0.477 -0.018 0.0015 <0.001 
Fish oil -7.3 8.5  -7.8 9.3  
BPRS psychotic 
subscale 
Placebo -2.4 3.2 0.850 -2.5 3.3 0.656 
0.912 -0.006 0.0005 <0.001 
Fish oil -2.3 2.5  -2.3 3.1  
SANS total 
Placebo -6.5 11.7 0.139 -6.2 11.7 0.894 
0.825 -0.018 0.0020 <0.001 
Fish oil -5.9 9.6  -7.5 11.7  
SANS affective 
flattening or blunting 
Placebo -1.8 4.6 0.237 -1.4 4.8 0.894 
0.491 -0.005 0.0008 <0.001 
Fish oil -1.9 4.0  -2.2 4.8  
SANS alogia 
Placebo -0.8 2.6 0.137 -0.6 2.4 0.596 
0.618 -0.002 0.0004 <0.001 
Fish oil -0.8 2.4  -1.1 2.5  
SANS avolition–apathy 
Placebo -1.4 3.0 0.448 -1.5 3.4 0.725 
0.598 -0.004 0.0005 <0.001 
Fish oil -1.3 2.8  -1.7 2.9  
SANS anhedonia–
asociality 
Placebo -2.1 4.0 0.397 -2.3 4.3 0.801 
0.587 -0.005 0.0007 <0.001 
Fish oil -1.7 3.5  -2.0 4.3  
SANS attention 
Placebo -0.4 1.4 0.224 -0.3 1.5 0.205 
0.925 -0.001 0.0003 <0.001 
Fish oil -0.3 1.8  -0.7 1.8  
YMRS total 
Placebo -1.1 3.0 0.244 -0.9 2.6 0.612 
0.696 -0.002 0.0005 <0.001 
Fish oil -0.9 3.1  -0.8 3.1  
MADRS total 
Placebo -9.3 8.4 0.093 -9.0 -9.6 0.717 
0.788 -0.020 0.0016 <0.001 
Fish oil -7.9 8.7  -9.6 -9.4  
SOFAS 
Placebo 12.6 14.9 0.066 14.3 16.8 0.949 
0.362 0.036 0.0030 <0.001 
Fish oil 8.9 16.5  14.7 19.1  
Global functioning: 
social 
Placebo 0.6 1.4 0.452 0.7 1.6 0.471 
0.406 0.002 0.0003 <0.001 
Fish oil 0.5 1.2  0.5 1.4  
Global functioning: role 
Placebo 0.9 1.6 0.017 1.0 2.0 0.782 
0.634 0.002 0.003 <0.001 
Fish oil 0.5 1.7  0.9 1.7  
1 P-value for comparing placebo and omega-3 groups in terms of change between follow-up (Month 6 or 12) and baseline. 
2 P-value for comparing placebo and omega-3 groups in terms of rate of improvement over time from baseline to Month 12. 
3 P-value for the overall estimated rate of change. 
 
Supplementary Table 1: Baseline demographic data for the study cohort 
 Placebo Fish oil 
Age, years 18.9±4.3 19.4±4.8 
Gender (% subjects) Female 59.6 49.0 
Race (% subjects) 
Caucasian 80.1 80.4 
Black or African American 2.6 2.0 
Asian 10.6 13.1 
Other 3.3 3.3 
Missing 3.3 1.3 
Highest level of education 
(% subjects) 
Primary school 37.1 35.9 
Secondary school, discontinued 17.9 17.6 
Secondary school, completed 27.8 28.8 
Trade or technical training 9.9 10.5 
Undergraduate university course 3.3 5.9 
Missing 4.0 1.3 
 
  
Supplementary Table 2: Baseline symptomatology in the study cohort 
Symptom measure Mean SD 
BPRS 
Placebo 40.7 8.9 
Fish oil 41.9 10.6 
SANS 
Placebo 17.4 12.9 
Fish oil 19.2 13.4 
YMRS 
Placebo 3.0 2.9 
Fish oil 3.3 3.1 
MADRS 
Placebo 19.1 9.2 
Fish oil 19.4 8.9 
SOFAS 
Placebo 53.5 12.2 
Fish oil 53.2 11.8 
Global functioning (social) 
Placebo 6.5 1.3 
Fish oil 6.5 1.2 
Global functioning (role) 
Placebo 5.9 1.5 
Fish oil 6.0 1.5 
 
  









7.9 12.4 0.272 
Extrapyramidal 3.3 8.5 0.094 
Gastrointestinal 27.2 34.6 0.198 
Hormonal 8.6 5.2 0.349 
Increased bleeding 0.7 0 0.995 
Neurological 5.3 9.8 0.205 
Psychological 9.9 13.1 0.498 
Sexual 0.7 4.6 0.076 
Skin 4.6 3.3 0.751 
Sleep-related 16.6 13.7 0.597 
Other 14.6 16.3 0.789 
* The p-value of the Chi-square test. 
 
 
